IL233712A0 - Sulfonamide derivatives used as mogat–2 inhibitors - Google Patents
Sulfonamide derivatives used as mogat–2 inhibitorsInfo
- Publication number
- IL233712A0 IL233712A0 IL233712A IL23371214A IL233712A0 IL 233712 A0 IL233712 A0 IL 233712A0 IL 233712 A IL233712 A IL 233712A IL 23371214 A IL23371214 A IL 23371214A IL 233712 A0 IL233712 A0 IL 233712A0
- Authority
- IL
- Israel
- Prior art keywords
- mogat
- inhibitors
- derivatives useful
- sulfonamide derivatives
- benzyl sulfonamide
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical class NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261592717P | 2012-01-31 | 2012-01-31 | |
| EP12382432 | 2012-11-06 | ||
| PCT/US2013/022870 WO2013116075A1 (en) | 2012-01-31 | 2013-01-24 | Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL233712A0 true IL233712A0 (en) | 2014-09-30 |
Family
ID=47148691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL233712A IL233712A0 (en) | 2012-01-31 | 2014-07-17 | Sulfonamide derivatives used as mogat–2 inhibitors |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8575352B2 (OSRAM) |
| EP (1) | EP2809651B1 (OSRAM) |
| JP (1) | JP2015511232A (OSRAM) |
| KR (1) | KR20140106750A (OSRAM) |
| CN (1) | CN104066719B (OSRAM) |
| AP (1) | AP2014007794A0 (OSRAM) |
| AR (1) | AR089771A1 (OSRAM) |
| AU (1) | AU2013215468A1 (OSRAM) |
| BR (1) | BR112014018636A8 (OSRAM) |
| CA (1) | CA2859995A1 (OSRAM) |
| CL (1) | CL2014001861A1 (OSRAM) |
| CO (1) | CO7010839A2 (OSRAM) |
| CR (1) | CR20140322A (OSRAM) |
| DO (1) | DOP2014000178A (OSRAM) |
| EA (1) | EA201491276A1 (OSRAM) |
| ES (1) | ES2590929T3 (OSRAM) |
| GT (1) | GT201400167A (OSRAM) |
| HK (1) | HK1199025A1 (OSRAM) |
| IL (1) | IL233712A0 (OSRAM) |
| MA (1) | MA35886B1 (OSRAM) |
| MX (1) | MX2014008599A (OSRAM) |
| PE (1) | PE20141679A1 (OSRAM) |
| PH (1) | PH12014501711A1 (OSRAM) |
| SG (1) | SG11201404106QA (OSRAM) |
| TW (1) | TW201343629A (OSRAM) |
| WO (1) | WO2013116075A1 (OSRAM) |
| ZA (1) | ZA201404836B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013112323A1 (en) | 2012-01-23 | 2013-08-01 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors |
| US8993568B2 (en) | 2012-01-31 | 2015-03-31 | Eli Lilly And Company | Morpholinyl derivatives useful as MOGAT-2 inhibitors |
| CN104768941B (zh) | 2012-11-06 | 2016-08-24 | 伊莱利利公司 | 用作MoGAT-2抑制剂的新苄基磺酰胺化合物 |
| MX389242B (es) | 2015-06-15 | 2025-03-20 | Nmd Pharma As | Compuestos para su uso en el tratamiento de trastornos neuromusculares |
| TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| WO2020145369A1 (ja) | 2019-01-11 | 2020-07-16 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1655283A1 (en) * | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
| EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| CN101087771A (zh) * | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物 |
| EP1824837B1 (en) * | 2004-11-10 | 2008-08-13 | Pfizer, Inc. | Substituted n-sulfonylaminobenzyl-2-phenoxy acetamide compounds |
| CA2662766C (en) * | 2006-09-08 | 2011-08-09 | Pfizer Products Inc. | Diaryl ether derivatives and uses thereof |
| EP2078719A4 (en) * | 2006-09-28 | 2009-11-11 | Dainippon Sumitomo Pharma Co | COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION |
| CA2669311C (en) * | 2006-11-13 | 2011-09-20 | Pfizer Products Inc. | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| AU2010216633A1 (en) | 2009-02-23 | 2011-09-08 | Msd K.K. | Pyrimidin-4(3H)-one derivatives |
| WO2013112323A1 (en) | 2012-01-23 | 2013-08-01 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors |
| US8993568B2 (en) | 2012-01-31 | 2015-03-31 | Eli Lilly And Company | Morpholinyl derivatives useful as MOGAT-2 inhibitors |
-
2013
- 2013-01-21 AR ARP130100180A patent/AR089771A1/es unknown
- 2013-01-21 TW TW102102260A patent/TW201343629A/zh unknown
- 2013-01-24 CN CN201380007085.XA patent/CN104066719B/zh active Active
- 2013-01-24 AP AP2014007794A patent/AP2014007794A0/xx unknown
- 2013-01-24 PE PE2014001197A patent/PE20141679A1/es not_active Application Discontinuation
- 2013-01-24 SG SG11201404106QA patent/SG11201404106QA/en unknown
- 2013-01-24 JP JP2014555589A patent/JP2015511232A/ja not_active Ceased
- 2013-01-24 US US13/748,627 patent/US8575352B2/en not_active Expired - Fee Related
- 2013-01-24 EP EP13703234.8A patent/EP2809651B1/en active Active
- 2013-01-24 AU AU2013215468A patent/AU2013215468A1/en not_active Abandoned
- 2013-01-24 WO PCT/US2013/022870 patent/WO2013116075A1/en not_active Ceased
- 2013-01-24 HK HK14112466.4A patent/HK1199025A1/xx unknown
- 2013-01-24 KR KR1020147021127A patent/KR20140106750A/ko not_active Ceased
- 2013-01-24 BR BR112014018636A patent/BR112014018636A8/pt not_active IP Right Cessation
- 2013-01-24 CA CA2859995A patent/CA2859995A1/en not_active Abandoned
- 2013-01-24 MX MX2014008599A patent/MX2014008599A/es unknown
- 2013-01-24 ES ES13703234.8T patent/ES2590929T3/es active Active
- 2013-01-24 EA EA201491276A patent/EA201491276A1/ru unknown
-
2014
- 2014-06-30 ZA ZA2014/04836A patent/ZA201404836B/en unknown
- 2014-07-04 CR CR20140322A patent/CR20140322A/es unknown
- 2014-07-15 CL CL2014001861A patent/CL2014001861A1/es unknown
- 2014-07-17 IL IL233712A patent/IL233712A0/en unknown
- 2014-07-24 MA MA37244A patent/MA35886B1/fr unknown
- 2014-07-24 CO CO14161422A patent/CO7010839A2/es unknown
- 2014-07-29 GT GT201400167A patent/GT201400167A/es unknown
- 2014-07-30 DO DO2014000178A patent/DOP2014000178A/es unknown
- 2014-07-30 PH PH12014501711A patent/PH12014501711A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2809651B1 (en) | 2016-06-29 |
| CO7010839A2 (es) | 2014-07-31 |
| MX2014008599A (es) | 2014-08-22 |
| AU2013215468A1 (en) | 2014-07-10 |
| TW201343629A (zh) | 2013-11-01 |
| CN104066719B (zh) | 2016-08-24 |
| EP2809651A1 (en) | 2014-12-10 |
| CN104066719A (zh) | 2014-09-24 |
| JP2015511232A (ja) | 2015-04-16 |
| CA2859995A1 (en) | 2013-08-08 |
| KR20140106750A (ko) | 2014-09-03 |
| PE20141679A1 (es) | 2014-11-08 |
| BR112014018636A8 (pt) | 2017-07-11 |
| SG11201404106QA (en) | 2014-08-28 |
| CL2014001861A1 (es) | 2014-11-07 |
| MA35886B1 (fr) | 2014-12-01 |
| EA201491276A1 (ru) | 2014-10-30 |
| US8575352B2 (en) | 2013-11-05 |
| GT201400167A (es) | 2015-05-28 |
| BR112014018636A2 (OSRAM) | 2017-06-20 |
| AP2014007794A0 (en) | 2014-07-31 |
| ZA201404836B (en) | 2017-08-30 |
| US20130197039A1 (en) | 2013-08-01 |
| ES2590929T3 (es) | 2016-11-24 |
| AR089771A1 (es) | 2014-09-17 |
| DOP2014000178A (es) | 2014-08-31 |
| PH12014501711A1 (en) | 2014-10-13 |
| WO2013116075A1 (en) | 2013-08-08 |
| HK1199025A1 (en) | 2015-06-19 |
| CR20140322A (es) | 2014-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201501009B (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| ZA201409422B (en) | Benzimidazole-proline derivatives | |
| LT2841428T (lt) | Dnr-pk inhibitoriai | |
| ZA201305826B (en) | Substituted amminobutyric derivatives as neprilysin inhibitors | |
| ZA201408876B (en) | Pyrrolotriazinone derivatives | |
| AP2014007794A0 (en) | Benzyl sulfonamide derivatives useful as mogat-2 inhibitors | |
| EP2870140B8 (en) | Tetrahydroquinazolinone derivatives as parp inhibitors | |
| IL247639B (en) | History of heteroaryl piperidine | |
| PT2718271E (pt) | Derivados de benzamida substituídos | |
| PL2838883T3 (pl) | Nowe pochodne fenylo-tetrahydroizochinoliny | |
| ZA201502175B (en) | Oxazolidin-2-one-pyrimidine derivatives | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| ZA201405227B (en) | Novel morpholinyl derivatives useful as mogat-2 inhibitors | |
| SG11201404325VA (en) | Pyrimidooxazocine derivatives as mtor - inhibitors | |
| ZA201502878B (en) | Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors |